Metabolic differences underlying two distinct rat urinary phenotypes, a suggested role for gut microbial metabolism of phenylalanine and a possible connection to autism  by Clayton, T. Andrew
FEBS Letters 586 (2012) 956–961journal homepage: www.FEBSLetters .orgHypothesis
Metabolic differences underlying two distinct rat urinary phenotypes,
a suggested role for gut microbial metabolism of phenylalanine and a possible
connection to autism
T. Andrew Clayton
The Winston Churchill School, Hermitage Road, St. Johns, Woking, Surrey GU21 8TL, UKa r t i c l e i n f o
Article history:
Received 2 November 2011
Revised 8 January 2012
Accepted 23 January 2012
Available online 1 February 2012
Edited by Judit Ovádi
Keywords:
Chlorogenic acid
Phenylalanine
Bacteria
Clostridia
Autism
Indolylacryloylglycine0014-5793/$36.00  2012 Federation of European Bio
doi:10.1016/j.febslet.2012.01.049
E-mail address: a.clayton@wcsc.org.uka b s t r a c t
A novel explanation is proposed for the metabolic differences underlying two distinct rat urinary
compositional phenotypes i.e. that these may arise from differences in the gut microbially-mediated
metabolism of phenylalanine. As part of this hypothesis, it is further suggested that elements of the
mammalian gut microbiota may convert phenylalanine to cinnamic acid, either by means of an
ammonia lyase-type reaction or by means of a three step route via phenylpyruvate and phenyllac-
tate. The wider signiﬁcance of such conversions is discussed with similar metabolism of tryptophan
and subsequent glycine conjugation potentially explaining the origin of trans-indolylacryloylgly-
cine, a postulated marker for autism.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Metabolite proﬁling
Metabolite proﬁling (‘metabonomics’/‘metabolomics’) is a rap-
idly growing area of analytical science that has immense biomed-
ical potential, with urine samples being particularly informative,
convenient to obtain and analyse [1]. A particular strength of this
still-developing analytical approach is that metabolite proﬁles
are sensitive to a whole range of factors, both genomic and envi-
ronmental, and, thereby, provide a multifactorial overview of a
subject’s status. In one general application of this ‘systems biology’
approach, the changes that are induced in endogenous metabolite
proﬁles by stressors, such as drugs and toxins, are monitored and
evaluated [1]. However, ‘baseline’ metabolite proﬁles are also
highly informative and may, for instance, be indicative of gender,
other genetic factors, dietary status or disease [1,2]. A great deal re-
mains to be understood regarding the signiﬁcance of inter-subject
variation in baseline metabolite proﬁles and, to do so, such varia-
tion has to be correlated with known factors. One new approach,
called ‘pharmaco-metabonomic phenotyping’, or simply ‘pharma-
cometabonomics’, has considerable potential to reveal the hidden
signiﬁcance of baseline metabolite proﬁles [3,4]. Thus, in a ﬁrst
study in humans [4], the presence of high levels of p-cresol sulfate
in the urine has been associated with a lower residual sulfonationchemical Societies. Published by Ecapacity and an important and hitherto-unrecognised effect of the
gut microbiota on paracetamol (acetaminophen) metabolism has
been demonstrated. That study provides an important insight into
the impact of the gut microbiota on drug metabolism [5] whilst
also serving as a reminder of the major role gut microbes play in
dictating urinary composition [6]. The present report further dis-
cusses the impact of the gut microbiota on baseline urinary metab-
olite proﬁles and addresses the origins of two different rat urinary
phenotypes.2. The ‘chlorogenic acid’ phenotype and its origins
Rats are an important experimental model for many investiga-
tions and, in recent years, there have been repeated reports of two
distinct rat urinary phenotypes, which are not attributable to die-
tary differences [7–10]. These phenotypes, which may be readily
distinguished by 1H NMR spectroscopy, differ in the relative
amounts of hippurate (benzoyl glycine) and certain so-called
‘chlorogenic acid metabolites’. Thus, the ‘HIP’ phenotype, which
is generally regarded as the more typical and conventional pheno-
type [10,11], is characterised by a relatively high level of hippurate
whilst the chlorogenic acid (CA) phenotype is characterised by a
relatively low level of hippurate and by an increased amount of
3-(3-hydroxyphenyl)propionic acid (3-HPPA) [7–10]. Additionally,
increased urinary amounts of two other metabolites have beenlsevier B.V. All rights reserved.
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Fig. 1. The known microbially-mediated conversion, (a) of phenylalanine to
phenylacetic acid and, (b) of tyrosine to p-cresol. Key to compounds: 1, phenyl-
alanine; 2, phenylpyruvic acid; 3, phenylacetic acid; 4, tyrosine; 5, 4-hydroxyphe-
nylpyruvic acid; 6, 4-hydroxyphenylacetic acid; 7, p-cresol. The structural
representations provided are not intended to convey any stereochemical informa-
tion. In humans, phenylacetic acid and p-cresol are further metabolised to
phenylacetylglutamine and p-cresol sulfate, respectively.
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increased levels of both 3-HPPA and 3-hydroxycinnamic acid
(3-HCA), whilst Robosky et al. [10] reported increased levels of
both 3-HPPA and 3-(4-hydroxyphenyl)propionic acid (4-HPPA).
Over time, the origin of these two distinct phenoptypes has
been ﬁrmly attributed to differences in the gut microbiota, with
rats of the CA phenotype being obtained frommicrobiologically-re-
stricted environments and being convertible to the HIP phenotype
by exposure to the normal laboratory environment or by cohabita-
tion with HIP rats, a procedure which would be expected to lead to
cross ingestion of faecal matter and of the associated microorgan-
isms [7,10,11]. Thus, it has become clear that CA rats are in some
way deﬁcient in the gut microbes that are necessary to produce
the HIP phenotype and, in one report, this deﬁciency has been
attributed to the initiation of colonies from Schaedler altered
microﬂora rats and to rigorous animal husbandry practices that
prevent or delay subsequent microbiological contamination [11].
However, despite apparent acceptance that the observed pheno-
typic difference is associated with differences in the metabolism
of dietary plant phenolics and that the observed 3-HPPA, 4-HPPA
and 3-HCA metabolites are derived from chlorogenic acid
[8,10,11], no clear explanation has been provided that details the
exact metabolic deﬁciency involved in producing the CA
phenotype.
In reviewing these earlier ﬁndings, the view was taken that the
CA phenotype might, to some extent, resemble an in-born error of
metabolism wherein a particular pathway is blocked or restricted
and ‘upstream’ metabolites are directly observed or are diverted
to different metabolic pathways. The work of Phipps et al. [7]
shows that rats of the CA phenotype are still capable of conjugating
benzoic acid with glycine to produce hippurate. Thus, it seemed
appropriate to consider the possibility that, in the CA phenotype,
a pathway that would otherwise lead to benzoic acid is restricted
and that 3-HCA, 3-HPPA and 4-HPPA are upstream metabolites
or are derived from such metabolites. Furthermore, in order for
blockage of this pathway to lead to a clearly detectable decrease
in urinary hippurate, it would need to provide a signiﬁcant propor-
tion of the benzoic acid utilised for urinary hippurate production in
HIP phenotype rats. From this viewpoint and having seen a report
that some human colonic bacteria can convert phenylalanine to
benzoic acid in a multistep process that has phenylpropionic acid
as an intermediate [12], it seemed possible that the origin of the
CA/HIP phenotypic difference might lie in the metabolism of phen-
ylalanine rather than in the metabolism of chlorogenic acid. This
hypothesis would also ﬁt with the assertion of Sakai et al. [13] that
serum hippuric acid is derived primarily from aromatic amino
acids by the metabolism of intestinal bacteria. At this point, it is
worth noting that sodium benzoate is used as a preservative in
some products consumed by humans but, in the absence of infor-
mation to the contrary, it is assumed that a signiﬁcant level of ben-
zoate was not present in the diets of the rats used in the studies
revealing the CA/HIP phenotypic difference. Furthermore, if, in
the HIP phenotype, most of the observed hippuric acid had been
derived from dietary benzoate, it would seem highly improbable
that the CA phenotype could have been observed, bearing in mind
the continued feasibility of benzoic acid–glycine conjugation in
rats of that phenotype [7].3. Relevant known and postulated metabolic pathways
Fig. 1 shows the microbially-mediated metabolism of phenylal-
anine to phenylacetic acid and of tyrosine to p-cresol [4,14]. These
pathways show much commonality but also a notable divergence
in that the presence of the p-hydroxy group in (tyrosine-derived)
4-hydroxyphenylacetic acid leads to loss of the acid group andthe formation of p-cresol. However, as indicated in the report of
Smith and Macfarlane [14], another bacterially-mediated meta-
bolic possibility exists for these two aromatic amino acid sub-
strates, phenylalanine and tyrosine, that seems particularly
relevant to the present topic. Thus, Smith and Macfarlane indicate
that aromatic amino acids (R–CH2–CH(NH2)–CO2H) may be con-
verted, via intermediates, to the corresponding aryl propionic acid
(R–CH2–CH2–CO2H). Evidence in support of such overall conver-
sion, by whatever mechanism, is provided by the studies of Moss
et al. [15], which show that phenylalanine may be converted to
3-phenylpropionic acid (PPA, hydrocinnamic acid) by certain spe-
cies of Clostridium, with cinnamic acid (a trans alkene) being a pos-
sible intermediate in that conversion. Likewise, studies by Lambert
and Moss [16] showed the production of 3-(4-hydroxyphenyl)pro-
pionic acid (4-HPPA) from tyrosine by Peptostreptococcus anaerobi-
us and, in this case, it was suggested that there may have been an
initial deamination to 4-hydroxycinnamic acid (4HCA; p-coumaric
acid) and subsequent reduction to 4-HPPA. In plants, the produc-
tion of cinnamic acid from phenylalanine is well known and is cat-
alysed by phenylalanine ammonia lyase (PAL) [17,18]. It is also
known that plants may further convert phenylalanine-derived cin-
namic acid to benzoic acid with evidence supporting a b-oxidation
type pathway [19]. However, whilst such reactions are best known
in plants, there is now also evidence that similar events occur in
some bacteria and fungi [18,20]. Thus, in Penicillium brevicompac-
tum, it has been established that cinnamate is an intermediate in
the conversion of l-phenylalanine to benzoate [21] whilst Moore
et al. [22,23] report that the sedimentary bacterium Streptomyces
maritimus produces benzoyl-CoA from phenylalanine in a plant-
like manner that involves a PAL-mediated conversion of phenylal-
anine to cinnamic acid. Such pathways appear to provide a new but
plausible explanation for the observed CA/HIP phenotypic
958 T.A. Clayton / FEBS Letters 586 (2012) 956–961difference, which might, seemingly, be related more to the gut
microbial metabolism of phenylalanine than to the gut microbial
metabolism of dietary plant phenolics. Relevant postulated meta-
bolic transformations are shown in Fig. 2.
As regards Fig. 2, the reactions of fatty acid b-oxidation could
account for the conversion to benzoic acid of both cinnamic acid
and 3-phenylpropionic acid, although the conversion of cinnamic
acid to benzoic acid might also proceed by a somewhat different
mechanism [19,24]. Blockage of those conversions would be
expected to lead to an initial build up of both cinnamic and 3-
phenylpropionic acids and, following such build up, aromatic
hydroxylation, a typical phase 1 metabolic conversion, would read-
ily explain the origin of the 3-HPPA and 3-HCA reported by Gava-
ghan et al. [8] and the origin of the 3-HPPA and 4-HPPA reported by
Robosky et al. [10]. Such hydroxylation might potentially be
achieved by elements of the gut microbiota [25]. However, aro-
matic hydroxylation is not, seemingly, a typical gut microbial con-
version [26] and the involvement of the host’s own cells in
achieving this conversion seems more likely. In parallel with what
is suggested here for phenylalanine, tyrosine would be expected to
undergo an initial deamination to p-coumaric acid. However, as
will be discussed below, tyrosine would not be expected to under-
go exactly the same metabolic conversions as phenylalanine and
the postulated divergence of phenylalanine and tyrosine metabo-
lism in Fig. 2 parallels the known metabolic divergence shown in
Fig. 1. The construction of Fig. 2 has been much inﬂuenced by
the report of Scheline [26], which states that the microbially-med-
iated decarboxylation of phenolic acids is favoured by the presence
of a p-hydroxyl group and has been observed with benzoic,CH2
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Fig. 2. Postulated metabolic pathways for phenylalanine and tyrosine. The red arrows i
might occur in the HIP phenotype but might not occur in the CA phenotype. The green
phenotype. The mauve box highlights three metabolites, higher urinary levels of whic
cinnamic acid; 3, 3-phenylpropionic acid (hydrocinnamic acid); 4, benzoic acid; 5, hippu
acid); 8, 4-vinylphenol; 9, 3-hydroxycinnamic acid (3-HCA); 10, 3-(3-hydroxyphenyl)p
hydroxybenzoic acid; 13, 3-hydroxybenzoic acid. The structural representations provided
and of 6–7 might proceed in a single step catalysed by some type of aromatic amino
conversions might proceed according to the scheme of Smith and Macfarlane [14]; se
performed by the host. The various hydroxylation reactions may also be non-microbial.phenylacetic and cinnamic acids but not with phenylpropionic
acids. If there is sufﬁcient opportunity for 4-HCA to undergo such
microbially-mediated decarboxylation, these metabolic factors
might account for the fact that, in the CA phenotype, both 3-HPPA
and 4-HPPA have been observed along with 3-HCA but not 4-HCA.
Furthermore, in Fig. 2, increased conversion of compound 2 to
compound 3 would readily explain why Robosky et al. [10] found
3-HPPA and 4-HPPA in the CA phenotype in contrast to the 3-
HCA and 3-HPPA reported by Gavaghan et al. [8]. The apparent
absence of 2-position (ortho) hydroxylation is also potentially
explicable, on the basis of steric hindrance. One signiﬁcant implica-
tion of the proposed reaction scheme shown in Fig. 2 concerns the
conversion of compounds 2 and 3 to benzoic acid, which might oc-
cur by the reactions of fatty acid b-oxidation. If, as suggested in
Fig. 2, failure of these conversions underlies the origin of the CA
phenotype, then it would appear that, in the HIP phenotype, such
conversions must be achieved by the gut microbiota rather than
by the host cells. However, another possibility is that, in producing
the CA phenotype, competitive utilisation of phenylalanine simply
reduces the availability of phenylalanine for benzoic acid produc-
tion. However, whatever the cause of the reduced urinary hippuric
acid excretion observed in the CA phenotype, there appears to be a
clear possibility that, in that phenotype, phenylalanine is con-
verted to cinnamic acid via a PAL-like deamination reaction with
subsequent hydroxylation and reduction occurring. However,
whilst the action of PAL, or similar, on phenylalanine presents a
plausible route to cinnamic acid, such conversion might also be
achieved according to the generalised scheme provided by Smith
and Macfarlane [14] for the metabolism of aromatic amino acids2
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Fig. 3. (a) Two possible routes from aromatic amino acids to the corresponding
trans-aryl alkenoic acids. 1 Designates an aromatic amino acid (phenylalanine,
tyrosine or tryptophan), where R is the appropriate aryl moiety, 2 is the
corresponding trans-aryl alkenoic acid, 3 is the corresponding aryl pyruvic acid
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established if the alkenoic acids produced by these two pathways would always
have the trans conﬁguration. The direct route from 1 to 2 requires the action of an
appropriate ammonia lyase e.g. phenylalanine ammonia lyase. The other suggested
possibility, an indirect route from 1 to 2, proceeds through 3 and 4 and follows the
scheme of Smith and Macfarlane [14]. If compound 1 was tryptophan, compound 2
would be trans-3-indolylacrylic acid (IAA) and glycine conjugation of IAA would
produce trans-indolylacryloylglycine (IAG), which has been proposed as a putative
marker for autism. If compound 1 was phenylalanine, compound 2 would be
cinnamic acid, which might potentially be metabolised to 3-(3-hydroxyphenyl)-3-
hydroxypropionic acid [32] by meta hydroxylation and the addition of water across
the double bond. If compound 1 was tyrosine, compound 2 would be 4-hydroxy-
cinnamic acid, which is also known as p-coumaric acid. (b) The structures of
tryptophan, indolylacrylic acid (IAA; 3-indoleacrylic acid) and indolylacryloylgly-
cine (IAG) shown in a simpliﬁed style without any intention to convey stereo-
chemical information.
T.A. Clayton / FEBS Letters 586 (2012) 956–961 959(AAA) by human intestinal bacteria. In that scheme, the relevant
metabolic route involves an initial conversion of the AAA to the
corresponding aromatic pyruvic acid and subsequent conversion
to the corresponding lactic acid before dehydration to an alkenoic
acid. Reduction of the alkenoic acid was indicated to produce the
corresponding propionic acid. Thus, whilst the respective
conversions of phenylalanine and tyrosine to cinnamic acid and
4-hydroxycinnamic acid, shown in Fig. 2, might involve one-step
ammonia lyase-type reactions, there is also a more established
multi-step possibility for each of these conversions, as discussed
by Smith and Macfarlane [14] and subsequently by Kim et al.
[27]. These two different possibilities are shown in Fig. 3a.
4. Signiﬁcance and a possible connection to autism
Metabolite proﬁling is proving to be an extremely powerful
investigative approach. However, for the results of such studies
to be interpreted correctly it is important to understand the factors
controlling the nature of baseline metabolite proﬁles. Any abnor-
mality in such proﬁles also raises a question regarding the statusof the subjects studied and the validity and relevance of the exper-
iments performed. However, understanding the origins of the CA/
HIP phenotypic difference is not only important in relation to
metabonomic/metabolomic studies in the rat and there is growing
recognition of the potential importance of the gut microbiota in
relation to disease and adverse drug reactions [5] with an abnor-
mal gut microﬂora potentially increasing or decreasing susceptibil-
ity according to the nature of each process. Thus, the present
considerations may have much wider signiﬁcance and, for exam-
ple, given the energy recovery value of fatty acid oxidation and
the reported association between obesity and an altered gut
microbiome [28], it is interesting to speculate that the CA pheno-
type might be associated with reduced energy recovery. However,
most notably and clearly, the present considerations have potential
relevance to the production of a postulated biomarker for autism,
trans-indolylacryloylglycine (IAG) [29] with autistic subjects also
having been associated with altered gut microbial populations
[30]. Thus, the ﬁrst metabolic steps shown in Fig. 2 for both phen-
ylalanine and tyrosine are deaminations that involve, or equate to,
the removal of ammonia. If the same metabolic transformation is
applied to tryptophan, trans-3-indolylacrylic acid (IAA) would be
produced and glycine conjugation of IAA would produce IAG. Nota-
bly, such deamination of tryptophan, if achieved via an ammonia
lyase reaction, would serve to provide a clear and direct one-step
route to IAA, in contrast to the more protracted and somewhat ob-
scure scheme described by Marklova [31] (see Supplementary
text). Making a further possible connection to autism, hydration
of 3-HCA (compound 9 in Fig. 2) could potentially explain the for-
mation of 3-(3-hydroxyphenyl)-3-hydroxypropionic acid, in-
creased urinary excretion of which has recently been reported in
autistic and schizophrenic subjects [32]. Further still, Lis et al.
[33] have reported elevated urinary levels of 4-hydroxyhippuric
acid in autistic subjects and the immediate pre-conjugation pre-
cursor of that compound, 4-hydroxybenzoic acid, could potentially
be derived from either phenylalanine or tyrosine (see Fig. 2) with
further literature evidence conﬁrming knownmicrobial conversion
of p-coumaric acid to 4-hydroxybenzoic acid [34,35]. Thus, whilst
the validity of IAG as a marker for autism has been challenged
[36], there are at least three possible markers for autism that might
be derived from the relevant aromatic amino acid via an initial
ammonia lyase reaction and only a very few subsequent metabolic
steps. This high degree of metabolic proximity suggests some con-
nection between autism and abnormal gut microbial metabolism
of aromatic amino acids. It is also notable, in view of the present
considerations and the known origin of human urinary phenyace-
tylglutamine (PAG) ([4] and Fig. 1a), that a recent metabonomic
study of autistic children, their unaffected siblings and age-
matched controls [37] indicated a trend towards decreased excre-
tion of hippurate and PAG in the autistic group. This also suggests
some connection between autism and abnormal gut microbial
metabolism of phenylalanine whilst the well known condition
phenylketonuria makes a clear connection between abnormal
phenylalanine metabolism and severe neurological symptoms;
children with untreated phenylketonuria often also having autism
[38].
As far as this author is aware, it remains to be established if
abnormal gut microbial metabolism of aromatic amino acids has
any role whatsoever in the development of autism. However, it
might perhaps be that, as previously suggested [4], gut bacterial
production of p-cresol (Fig. 1) is a signiﬁcant factor in regard to
autism, with Clostridium difﬁcile being one notable p-cresol pro-
ducer [39]. Thus, through its known inhibitory effect on dopamine
b-hydroxylase [40], p-cresol might directly affect the metabolism
of dopamine, which is an important neurotransmitter. Further-
more, childhood autism has been linked to impaired sulfonation
[41] and it has been clearly shown [4] that, through its own
960 T.A. Clayton / FEBS Letters 586 (2012) 956–961sulfonation, gut bacterially-produced p-cresol can signiﬁcantly re-
duce an individual’s sulfonation capacity with sulfonation being
hugely important for a variety of normal processes and structures,
for xenobiotic excretion and for catecholamine handling [42]. Fur-
ther still, through its inhibitory effect on dopamine b-hydroxylase
and the likely consequent excess of dopamine, this author consid-
ers that p-cresol production might readily explain the origins of
another possible urinary biomarker for autism, homovanillic acid
[43], which is the normal end product of dopamine degradation
[44]. In regard to the onset of autism during childhood, it is also
notable that sulfonation is considered to be especially important
during early human development with glucuronidation being un-
der-developed in the neonate [45,46]. In view of these consider-
ations, it is also particularly notable that direct experimental
evidence of a link between p-cresol and autism has recently been
obtained [47] (see Supplementary information).
5. Conclusions
The origins of the CA phenotype still require clariﬁcation. How-
ever, the ideas presented here appear to have some merit for
explaining the observed CA/HIP phenotypic difference and the ori-
gin of the benzoic acid that goes on to become urinary hippurate. If
the metabolites that characterise the CA phenotype are not solely
or almost entirely derived from chlorogenic acid, then the term
‘CA phenotype’ would appear to be a confusing misnomer and, as
a precautionary measure, it would seem safer to follow the exam-
ple of Williams et al. [9] and to refer instead to m-HPPA (3-HPPA)
excretors. However, whatever the precise origins of the HIP and CA
phenotypes, a key message of the present considerations is the
possibility that certain elements of the mammalian gut microbiota
might have PAL or similar activity and that such activity could
potentially explain the origins of various compounds that have
been linked to autism (Fig. 3). Alternatively, the scheme of Smith
and Macfarlane [14] shows that aryl alkenoic acids may be pro-
duced from aromatic amino acids by a multi-step pathway
(Fig. 3). Conceptually, it is certainly to be expected that particular
gut microbes and populations that provide unusual metabolic
capacities might have a role in the aetiology of various human dis-
eases as well as in the development of adverse drug reactions in
subsets of the human population [5]. It is also to be expected that
identifying such microbial species and populations and determin-
ing the relevant metabolic factors may require considerable re-
search effort. However, from the present discussion and given
the suggested link between autism and clostridia [48], it would
seem sensible to investigate if any species of clostridia inhabiting
the human gut are able to provide signiﬁcant activity of any aro-
matic amino acid ammonia lyase. Possession of PAL, or similar,
activity by elements of the clostridia would not be especially sur-
prising given the other unusual metabolic features of these bacte-
ria [49], some of which are notable toxin producers. Likewise, the
present considerations suggest that it would be useful to perform
a detailed survey, for each aromatic amino acid, to establish which
of the clostridia inhabiting the human gut are able, like Clostridium
sporogenes and phenylalanine [27], to metabolise that compound
to the corresponding trans-aryl alkenoic acid according to the
scheme of Smith and Macfarlane [14]. The justiﬁcation for such
investigations is to elucidate the potential origins of various com-
pounds linked to autism. Conceivably, it might also be worthwhile
to examine the fungal component of the gut microbiota for PAL
activity. The justiﬁcation here is that PAL occurs abundantly in
yeast [20,50] and that there has been some suggestion of a link be-
tween yeasts and autism and of improvements in autistic patients
following antifungal therapy. Thus, it is conceivable that fungal
degradation of phenylalanine has some role in autism. It is also
likely that, as with spore-forming clostridia, fungi such as Candidaare able to take a much stronger hold in the gut when, for reasons
such as extensive antibiotic treatment, the extent of normal gut
bacterial colonisation is much reduced.
In summary, consideration of the ‘chlorogenic acid’ urinary phe-
notype seen in rats, suggests possible gut microbial production of
cinnamic acid from phenylalanine. Such conversion might poten-
tially occur by either of the mechanisms shown in Fig. 3a with
the possible action of phenylalanine ammonia lyase representing
a particularly novel and interesting possibility. With similar gut
microbial conversion of phenylalanine, tyrosine and tryptophan
potentially explaining the origins of three compounds linked to
autism, and with clostridia and yeasts already suspected of
involvement in its aetiology, a survey of their capacity for effecting
such conversions may be warranted. It is also noted that the origins
of two other compounds linked to autism and the diminished
sulfonation capacity seen in autistic children might perhaps be
explained by the action of certain gut microbes on tyrosine.
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